QQ客服 官方微博 反馈留言

	The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial
	Wang, Lili; He, Zhen; Yang, Sen; Tang, Hong; Wu, Yufeng; Li, Shaomei; Han, Baohui; Li, Kai; Zhang, Li; Shi, Jianhua
刊名	TRANSLATIONAL LUNG CANCER RESEARCH
	2019
卷号	8期号:5页码:575-+
关键词	Non-small cell lung cancer (NSCLC) anlotinib antiangiogenic therapy
DOI	10.21037/tlcr.2019.09.21
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4550843
专题	山东大学
作者单位	Zhengzhou Univ, Canc Hosp, Oncol Dept, Zhengzhou 450008, Henan, P
推荐引用方式 GB/T 7714	Wang, Lili,He, Zhen,Yang, Sen,et al. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial[J]. TRANSLATIONAL LUNG CANCER RESEARCH,2019,8(5):575-+.
APA	Wang, Lili.,He, Zhen.,Yang, Sen.,Tang, Hong.,Wu, Yufeng.,...&Geng D.(2019).The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.TRANSLATIONAL LUNG CANCER RESEARCH,8(5),575-+.
MLA	Wang, Lili,et al."The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial".TRANSLATIONAL LUNG CANCER RESEARCH 8.5(2019):575-+.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。